First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Monika Knysak, Norbert Kwella, Anna Pawłowska, Tomasz Stompór, Justyna Zbrzeźniak-Suszczewicz

Ngôn ngữ: eng

Ký hiệu phân loại: 133.526 First six signs

Thông tin xuất bản: United States : Transplantation proceedings , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 702861

Thêm vào giỏ Liên kết toàn văn

Cytomegalovirus (CMV) is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs). In this article, we presented the case of a 39-year-old patient with end-stage renal disease after kidney transplantation with refractory CMV infection, who was successfully treated with maribavir for the first time in Poland. The use of maribavir resulted in a significant reduction of CMV viremia in ganciclovir/valganciclovir-resistant CMV infection and resolution of CMV disease symptoms in the absence of drug-related adverse events.

Tạo bộ sưu tập với mã QR